PMID- 26776481
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20220408
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 54
IP  - 1
DP  - 2016 Feb
TI  - Adverse events in apheresis: An update of the WAA registry data.
PG  - 2-15
LID - S1473-0502(16)00005-7 [pii]
LID - 10.1016/j.transci.2016.01.003 [doi]
AB  - Apheresis with different procedures and devices are used for a variety of 
      indications that may have different adverse events (AEs). The aim of this study 
      was to clarify the extent and possible reasons of various side effects based on 
      data from a multinational registry. The WAA-apheresis registry data focus on 
      adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs 
      were graded as mild, moderate (need for medication), severe (interruption due to 
      the AE) or death (due to AE). More AEs occurred during the first procedures 
      versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to 
      access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 
      58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures 
      (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 
      4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the 
      replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to 
      similar extents when using plasma or albumin as replacement. In 64% of procedures 
      with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are 
      rare. Although most reactions are mild and moderate, several side effects may be 
      critical for the patient. We present side effects in relation to the procedures 
      and suggest that safety is increased by regular vital sign measurements, cardiac 
      monitoring and by having emergency equipment nearby.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Mortzell Henriksson, M
AU  - Mortzell Henriksson M
AD  - Nephrol, Umea, Sweden.
FAU - Newman, E
AU  - Newman E
AD  - Bone Marrow Transplant & Apheresis, New South Wales, Australia.
FAU - Witt, V
AU  - Witt V
AD  - St. Anna, Vienna, Austria.
FAU - Derfler, K
AU  - Derfler K
AD  - AKH, Vienna, Austria.
FAU - Leitner, G
AU  - Leitner G
AD  - AKH, Vienna, Austria.
FAU - Eloot, S
AU  - Eloot S
AD  - Gent, Belgium.
FAU - Dhondt, A
AU  - Dhondt A
AD  - Gent, Belgium.
FAU - Deeren, D
AU  - Deeren D
AD  - Roeselar, Belgium.
FAU - Rock, G
AU  - Rock G
AD  - Canada.
FAU - Ptak, J
AU  - Ptak J
AD  - Frydek-Mistek, Czech Republic.
FAU - Blaha, M
AU  - Blaha M
AD  - Hradec Kralove, Czech Republic.
FAU - Lanska, M
AU  - Lanska M
AD  - Hradec Kralove, Czech Republic.
FAU - Gasova, Z
AU  - Gasova Z
AD  - Prague, Czech Republic.
FAU - Hrdlickova, R
AU  - Hrdlickova R
AD  - Ostrava, Czech Republic.
FAU - Ramlow, W
AU  - Ramlow W
AD  - Rostock, Germany.
FAU - Prophet, H
AU  - Prophet H
AD  - Rostock, Germany.
FAU - Liumbruno, G
AU  - Liumbruno G
AD  - Livorno, Italy.
FAU - Mori, E
AU  - Mori E
AD  - Livorno, Italy.
FAU - Griskevicius, A
AU  - Griskevicius A
AD  - Vilnius, Lithuania.
FAU - Audzijoniene, J
AU  - Audzijoniene J
AD  - Vilnius, Lithuania.
FAU - Vrielink, H
AU  - Vrielink H
AD  - Amsterdam, The Netherlands.
FAU - Rombout, S
AU  - Rombout S
AD  - Maastricht, The Netherlands.
FAU - Aandahl, A
AU  - Aandahl A
AD  - Oslo, Norway.
FAU - Sikole, A
AU  - Sikole A
AD  - Skopje, Macedonia.
FAU - Tomaz, J
AU  - Tomaz J
AD  - Coimbra, Portugal.
FAU - Lalic, K
AU  - Lalic K
AD  - Belgrade, Serbia.
FAU - Mazic, S
AU  - Mazic S
AD  - Zagreb, Croatia.
FAU - Strineholm, V
AU  - Strineholm V
AD  - Orebro, Sweden.
FAU - Brink, B
AU  - Brink B
AD  - Huddinge, Sweden.
FAU - Berlin, G
AU  - Berlin G
AD  - Linkoping, Sweden.
FAU - Dykes, J
AU  - Dykes J
AD  - Lund, Sweden.
FAU - Toss, F
AU  - Toss F
AD  - BC, Umea, Sweden.
FAU - Axelsson, C G
AU  - Axelsson CG
AD  - BC, Umea, Sweden.
FAU - Stegmayr, B
AU  - Stegmayr B
AD  - Nephrol, Umea, Sweden. Electronic address: bernd.stegmayr@umu.se.
FAU - Nilsson, T
AU  - Nilsson T
AD  - Nephrol, Uppsala, Sweden.
FAU - Norda, R
AU  - Norda R
AD  - BC, Uppsala, Sweden.
FAU - Knutson, F
AU  - Knutson F
AD  - BC, Uppsala, Sweden.
FAU - Ramsauer, B
AU  - Ramsauer B
AD  - Nephrol., Skovde, Sweden.
FAU - Wahlstrom, A
AU  - Wahlstrom A
AD  - Nephrol., Karlstad, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160108
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis 
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
RN  - 0 (Colloids)
RN  - SY7Q814VUP (Calcium)
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Component Removal/*adverse effects
MH  - Calcium/administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Colloids
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Plasma Exchange
MH  - Reference Standards
MH  - *Registries
MH  - *Societies, Medical
MH  - Time Factors
MH  - Tissue Donors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Adverse events
OT  - Albumin
OT  - Apheresis
OT  - Donor
OT  - Plasma
EDAT- 2016/01/19 06:00
MHDA- 2017/01/10 06:00
CRDT- 2016/01/19 06:00
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
AID - S1473-0502(16)00005-7 [pii]
AID - 10.1016/j.transci.2016.01.003 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2016 Feb;54(1):2-15. doi: 10.1016/j.transci.2016.01.003. Epub 
      2016 Jan 8.